Article Text

Download PDFPDF

Flucelvax Tetra: a surface antigen, inactivated, influenza vaccine prepared in cell cultures
  1. Silja Bühler1,2,
  2. Michael Ramharter2,3
  1. 1 Department of Public Health/Division of Infectious Diseases, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland
  2. 2 Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine and I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
  3. 3 Centre de Recherches Médicales de Lambaréné, Albert Schweitzer Hospital, Lambaréné, Gabon
  1. Correspondence to Silja Bühler; si.buehler{at}uke.de

Statistics from Altmetric.com

On 18 October 2018, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on the inactivated cell-based quadrivalent influenza vaccine Flucelvax Tetra for the use in adults and in children aged 9 years and above.1 Influenza is a major cause of illness and mortality worldwide. Clinical attack rates often range from 10% to 20% in the general community during epidemics and can be as high as 50% in closed populations, such as schools or nursing homes.2 According to the WHO, influenza causes annually three to five million cases of severe respiratory tract infections and is estimated to result in 290 000–650 000 respiratory deaths per year globally.3 During pandemics, such as the 1918 pandemic, the death toll has been estimated to be as high as 40 million.2 Vaccination against influenza does not confer complete protection but it has been consistently shown to have an important impact on morbidity and has therefor become an important public health intervention to protect vulnerable patient populations. Since many years several commercial influenza vaccine products are available in Europe, so that one have to ask what are the advantages of the latest registered influenza vaccine …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.